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Interferons (IFNs) are proteins with a wide rangeofbiological effects. IFNs have antiviral and
antiproliferative properties. They modulate both the immune system and the expression of cell
phenotype. In the past decade, the IFNs have received intense clinical scrutiny. Alpha IFN is the
best studied anddisplays activity in manyneoplasticdiseases; it hasshown the most promise in the
hematological cancers although several solid tumors, including epidemic Kaposi's sarcoma, renal
cell carcinoma, and melanoma, respond. No neoplastic disease, however, has been cured by the
IFNs. IFN seems to be most active in the setting ofminimal residual disease, and clinical studies
evaluating its role in the adjuvant setting are under way. Other areas of research include trials
combining IFN with cytotoxicdrugsorother biological response modifiers, and maintenance IFN
to prolong remissions following successful induction therapy.
INTRODUCTION
Researchers recognized in 1957 that cultured cells exposed to heat-inactivated virus
produced a substance that conferred cellular resistance to subsequent lytic viral
infection [1]. This substance was named interferon (IFN) and was later shown to be a
group of related protein cytokines produced by many different cells in response to
viruses, ds RNA, and other agents. IFNs inhibit viral replication, modulate immune
function, and have a direct antiproliferative effect on tumor cells. They are classified
according to antigenic and physicochemical properties into three major types: alpha
(leukocyte), beta (fibroblast), and gamma (immune) IFNs [2]. Many subtypes of
alpha IFN have been characterized; these subtypes share a 75 percent homology in
amino acid sequence and show some differences in biological activity [3].
Only one protein species has been identified for beta IFN; this protein shares a 29
percent homology ofamino acid sequencewith alpha IFN [4]. Beta IFN wasoriginally
obtained from stimulated fibroblasts, but, like alpha IFN, it can be produced by
virtually any cell under the proper stimulus. Alpha and beta IFNs have been termed
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type I IFNs because of their stability at low pH [4]. These IFNs bind to the same cell
surface receptor [5].
Gamma IFN, produced by activated T lymphocytes, is labile in an acid environment
and is called a type II IFN. The degree of homology between alpha and gamma IFN
may be about 12 percent but is currently debated [6]. Gamma IFN has a cellular
receptor distinct from the type I IFNs [7].
The first clinical trials of IFN involved a partially purified polyclonal mixture of
alpha IFN produced by leukocytes obtained from banked transfusion blood [8]. In
terms of IFN protein, this preparation was about 0.5 percent pure, extremely
expensive, and available only in minute quantities. In 1975, Finter introduced a
method for obtaining large amounts of natural alpha IFN from stimulated lympho-
blastoid cells. This product contained many different subtypes of alpha IFN and has
been marketed as IFN-a-nl [9]. Production ofa single subtype of a IFN subsequently
became possible through recombinant DNA technology. Two recombinant products,
IFN-a-2a and IFN-a-2b have been marketed in the U.S.A. These IFNs differ in
composition by only one amino acid and probably represent allelicvariants ofthe same
subtype [10]. The U.S. FDA recently approved the useofthese two recombinant IFNs
for the treatment ofhairy cell leukemia (HCL) and Kaposi's sarcoma.
BIOLOGICAL ACTIVITY
Alpha IFN has numerous biologic effects which can be grouped into four major
categories: antiviral [11], antiproliferative [2,12], immunomodulatory [13-15], and
alteration of cell phenotype (including expression of tumor-associated antigens and
oncogenes) [16-18]. These effects are mediated via specific cell surface receptors. The
antiviral activity of IFN depends, at least in part, on the activation of endonuclease.
This enzyme inhibits protein synthesis by cleaving viral and host RNA [19-23]. Other
mechanisms proposed from cell culture data include impairment of 5'-methylation of
newly synthesized RNA, inhibition of phosphodiesterase, and inhibition of virus
maturation and budding [19,24].
The direct antiproliferative activity of IFN has been established both in cell culture
and in immunodeficient nude mice. The mechanism for this effect has not yet been
determined. Cell cycle changes prolonging each phase ofthe cell cycle and the overall
cell generation time have been described [3] and result in cytostatic and possibly
cytotoxic effects [25]. Some studies suggest that changes in cell cycle phases may
result from DNA polymerase inhibition, from a loss of coordination between DNA
replication and subsequent cell division [19], or from inhibition of the polyamine
synthesis pathway [26]. Alternatively, IFNs may affect proliferation and differentia-
tion via modification of oncogene expression. This modulation appears to play an
important role in the normalization ofcell growth and the disappearance ofmalignant
characteristics [16,17,27-31].
Alteration of immune function includes effects on monocyte, neutrophil, natural
killer (NK) activity, T-cell cytotoxicity, and B-cell immunoglobulin production.
Various studies have yielded conflicting results as to the type ofeffect IFN has on these
immune cells. The differences are due in part to a lack of standardization of assays
used to measure immune function. Great disparity exists in how immune cells are
collected, separated, stimulated, and cellular function measured [31]. Certain trends,
however, are apparent in most studies, and these effects are listed in Table 1. IFN
frequently inhibits immune cell function, and this effect may be related to its
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TABLE I
In Vivo Immunomodulatory Effects of Alpha IFN
Immune Component Effect Reference
B lymphocyte Decrease in immunoglobulin pro- [32,33]
duction
T lymphocyte Decreased proliferative response to [31,32]
mitogens and mixed lymphocyte
culture
Monocyte Increased Fc receptor-mediated [31]
phagocytosis
NK cell Short-term increase usually fol- [31-33]
lowed by a decline in activity [34,35]
Antibody-dependent cellular Variable effect [31,35]
cytotoxicity (ADCC)
MHC phenotype Increased expression ofclass I and [13]
II antigens
Oncogene expression Variable effect [16-18,27-31,40-42]
ADCC, antibody-dependent cellular cytotoxicity; MHC, major histocompatibility complex
antiproliferative activity. IFN produces a decline in total lymphocyte count and
suppresses immunoglobulin production [32,33]. NK cell activity falls within hours of
an injection of IFN and then rebounds to levels above baseline one to three days after
the first dose [34,35]. Repeated IFN administration, however, results in diminished
NK activity in many, but not all, patients [31-33,34,35]. Future studies must clarify
which immunological mechanisms are involved in the antitumor effect so that the dose
and administration schedule of IFN can be optimized. Since many cancer patients
have selective defects in immune function, it will also beofinterest todetermine ifIFN
can reverse these defects and if reversal produces a clinical response. In addition, it
must be determined why chronic IFN exposure frequently produces hyporesponsive
NK cells and whether secondary malignancies or other clinical sequelae result from
this chronic immunosuppression.
The primary mechanisms of IFN antitumor action may be multifactorial and
dependent on the tumor type [36]. In viral-associated tumors such as laryngeal
papillomatosis and condyloma acuminatum, the antiviral effect of IFN may be
involved [37]. Clonogenic assays and immunodeficient nude mice models support a
direct antiproliferative effect rather than immunomodulation [38,39]. Inhibition of
oncogene expression may be important in some malignancies such as HCL and chronic
myeloid leukemia (CML) [40-42].
Beta and gamma IFNs share most of the biological effects of the alpha IFNs [43].
One important difference, however, relates to the expression of antigens of the major
histocompatibility complex (MHC). Although all the IFNs increase expression of
MHC antigens, gamma IFN is significantly more potent than the other IFNs in
modulating the class II antigens [13]. Other important immunomodulatory effects of
gamma IFN include stimulation ofmonocyte function [3] and promotion ofmicrobici-
dal killing via superoxide generation [44].
DISTRIBUTION AND TOXICITY
IFNs are small protein molecules with molecular weights ranging from approxi-
mately 20,000 daltons for alpha and beta IFN to about 70,000 daltons for gamma
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IFN. The pharmacokinetics of recombinant and natural alpha IFN are comparable
[45-47]. Alpha IFN passes freely between the blood and extravascular pools.
Cerebrospinal fluid (CSF) penetration is poor, with serum-to-CSF ratio varying from
67:1 to 1,100:1 [48-51]. Animal studies indicate that alpha IFNs are rapidly filtered
by the glomeruli and catabolized in the renal tubules. Although alpha IFN is
non-dialyzable, low-dose therapy in hemodialysis patients has not led to drug accumu-
lation [52-54].
Intravenous administration of all three classes of IFN results in high peak
concentrations followed by a rapid decline from the serum. Lower peak serum
concentrations and longer serum half-lives can be obtained by using the intramuscular
or subcutaneous routes. Using equivalent doses, intramuscular injection ofalpha IFN
results in peak serum levels that are only about 10 percent of the maximal levels
observed after intravenous administration [55].
Most side effects of IFN are dose-dependent, more conspicuous in the elderly, and
are reversible when treatment is stopped [56-58]. At the dose range recommended for
HCL (3 x 106 U three times a week or less), side effects from IFN are usually mild.
Studies evaluating high-dose IFN, with daily doses greater than 20 x 106 U,
frequently result in severe toxicity requiring dose modification. Except for minor
quantitative differences, it appears that the toxicities of beta and gamma IFN are
similar to that of alpha IFN [59-63]. The most common adverse effect is an acute
influenza-like syndrome seen in more than 95 percent of the patients [56-58]. In
patients receiving IFN at least three times weekly, these symptoms usually decrease in
intensity and dissipate within seven to ten days of continued therapy. They can recur
though, iftherapy is interrupted [58].
The other side effects of IFN are subacute or chronic. Common neurological effects
include fatigue, weakness, anorexia, and an inability to concentrate. Large systemic
doses (>100,000 x 106 U daily) produce psychoses, confusion, seizures, and psycho-
motor retardation [64-66]. These effects have been the dose-limiting toxicities in the
majority ofclinical trials and do not tend to decrease with time [56-58].
Hematologic toxicity can be seen in all cell lines but is most pronounced in white
cells. Leukopenia occurs consistently within hours after administration. A decrease of
approximately 50 percent in the leukocyte count is frequently observed after the first
week oftreatment, but the count rapidly recovers once treatment is discontinued. This
result and bone marrow studiessuggest that IFN causes redistribution ofthe white cell
population rather than myelosuppression [56-58,671. Anemia due to IFN therapy is
dose-related. When it occurs, it is usually normochromic, normocytic, and may require
weeks to months for recovery [56-58]. Rare cases of Coombs' positive hemolytic
anemia have been reported [58,68]. Interferon-induced thrombocytopenia is rare in
patients with solid tumors but has been reported in 25-50 percent of patients with
chronic lymphocytic leukemia and multiple myeloma [58]. A few cases of immune-
mediated thrombocytopenia and coagulopathy induced by IFN have also been
described [69-71].
Cardiovascular toxicities, such as tachycardia and hypotension, are usually related
to the flu-like syndrome [58]. Effects on thegastrointestinal system (including nausea,
vomiting, and diarrhea) are generally mild and occur in approximately one-third of
patients. Elevation of hepatic transaminases is frequently seen but is rarely clinically
significant. The most common renal toxicity is mild proteinuria [56-58], although rare
cases of acute renal failure and nephrotic syndrome have been described [72,73]. The
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most prominent dermatologic reactions are mild alopecia and transient skin rashes.
The paradoxic profuse growth ofeyelashes has also been seen [74].
Other rare side effects include autoimmune thyroid disease (hyperthyroidism and
hypothyroidism), parotitis, epididymitis, pernicious anemia, and systemic lupus ery-
thematosus [75-79]. IFN has also been shown to depress the drug-metabolizing
hepatic cytochrome P-450 system and could potentially predispose to drug interactions
[80]. Although this effect has not been ofmajorclinical significance thus far, enhanced
phenobarbital toxicity was reported in one case [81]. With the incorporation of
interferon into multi-drug regimens, it will be important to remain vigilant for other
potential drug interactions.
Since alpha IFN currently represents primarily a palliative treatment modality,
special attention must be directed toward minimizing toxicity while not compromising
efficacy. Administration of IFN at bedtime, preceded by acetaminophen and a
benzodiazepine, improves patient tolerance by minimizing fever and chills and
allowing patients to "sleep through" other potential side effects which often occur
during the first week oftherapy.
IFN NEUTRALIZING ANTIBODIES
Both natural and recombinant human alpha and beta IFNs can be antigenic in man
[58]. The antigenic potential ofgamma IFN is currently being evaluated but appears
to be low. Factors affecting antibody (Ab) formation include the dose and schedule of
IFN and the type ofmalignancy. Peak Ab titers occur five days following cessation of
IFN therapy. Depending on the type of assay used, Abs are detectable in 2.5-25
percent of patients. Controversy exists as to the relative antigenicity of the two
approved recombinant IFN preparations. Differences determined in some studies may
simply reflect differences in the sensitivities of the Ab assay employed [57,82,83].
Some Abs induced by one recombinant IFN cross-react with the other recombinant
preparation. In vitro studies, however, show no cross-reactivity of recombinant IFN
Abs with partially purified natural IFN [24].
The clinical relevance of neutralizing antibodies remains unclear. Reports of
patients whose response was potentially shortened due to antibody formation, however,
are increasing in the literature [58,83-85]. Steis et al. [24] recently reported on 51
hairy cell leukemia patients treated with recombinant alpha IFN. Of the 16 patients
who developed neutralizing antibodies in this series, six also became clinically resistant
to IFN. This result suggests that in some cases clinical resistance to IFN may be
through the development of IFN-neutralizing antibodies. Other mechanisms for
resistance must also occur, however, since the presence of antibodies does not
necessarily signal the end ofa clinical response.
CLINICAL APPLICATIONS IN ONCOLOGY
Although alpha IFNs have been extensively used in the clinic, the experience with
the other IFNs has been restricted to a relatively few phase I and phase II trials. Thus
far, neither beta nor gamma IFN has shown more activity than alpha IFN. Figures 1
through 3 summarize the results reported for malignancies in which IFN has been
extensively evaluated. For solid tumors and lymphomas, responses are defined in the
standard fashion: a complete response (CR) indicates disappearance of all evaluable
tumor, and a partial response (PR) means more than a 50 percent reduction in
measurable disease. The response criteria for the hematologic malignancies is defined
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in the text. These figures should be interpreted with caution since they aggregate data
from many studies which used alpha IFN in different dosage schemas and had a
different patient mix.
EXPERIENCE IN HEMATOLOGIC MALIGNANCIES
Hairy Cell Leukemia
Hairy cell leukemia (HCL) is a rare lymphoproliferative disorder which is relatively
refractory to standard cytotoxic agents. Since the first promising report by Quesada et
al. [86] in 1984, a number of clinical trials have been published in the treatment of
HCL with alpha IFN [85-97]. In these trials, a CR has usually been defined as a
peripheral hematologic remission with 5 percent or less hairy cells in the marrow and a
PR as a peripheral hematologic remission with 50 percent or greater reduction in
leukemic infiltration of the marrow. Most clinical trials have used IFN doses in the
range of 3 x 106 U subcutaneously or intramuscularly three times a week for
approximately one year. Lower doses have been evaluated, and although they result in
less fatigue, they are probably less efficacious [98,99]. Extending treatment an
additional six months after a year of therapy has not improved the CR rate nor
prolonged the interval until disease progression [100]. The CR rate is low with IFN, as
illustrated in Fig. 1; however, 70-90 percent ofpatients experience marked symptom-
atic and hematologic improvement. Theredoes not appear to be a significant difference
in response between splenectomized and non-splenectomized patients. Hematologic
improvement is gradual, with normalization of the platelet count usually occurring
within two months, and normalization ofthe hemoglobin and granulocyte count within
four to six months. Following discontinuation of IFN, the percentage of hairy cells
increases gradually in the marrow, with 45 percent of the patients requiring retreat-
ment at a median of 25.4 months because of progressive cytopenias [100,101].
Remissions can be re-induced with alpha IFN in most patients [85,95,96,100]. In
contrast to alpha IFN, gamma IFN appears to be inactive in HCL, a result which
correlates with different intracellular effects on hairy cells by the two types of IFN
[102].
Recently, a cytotoxicdrug pentostatin (2'-deoxycoformycin) has been shown to have
marked activity in HCL. The drug is well tolerated and produces a CR in >80 percent
ofthe patients treated. It is too early to assess late sequelae or determine ifpentostatin
can cure hairy cell leukemia [103]. A multi-institutional trial comparing pentostatin to
alpha IFN is currently under way.
Chronic Myeloid Leukemia
Chronic myeloid leukemia (CML) is a hyperproliferative disorder ofmultipotential
stem cells. The Philadelphia chromosome (Ph'), present in 90 percent ofthesepatients,
represents a reciprocal translocation (t9,22) involving the proto-oncogene c-abl. Based
on in vitro data showing that alpha IFN can inhibit proliferation ofboth leukemic and
normal myeloid colony formation and downregulate oncogene expression [104],
Talpaz et al. [105,106] investigated the effect of human leukocyte IFN in controlling
myeloid proliferation in chronic myeloid leukemia (CML). They employed doses of
alpha IFN ranging from 3 to 9 x 106 Udaily until hematologic remission was obtained,
followed by slightly lower doses for remission maintenance. Complete remission was
defined as normalization of white cell and platelet count and disappearance of
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splenomegaly. Decrease in white cell count to at least 50 percent ofpretreatment level
and below 20,000/,uL was called a PR. Ofthe 51 patients treated, 71 percent achieved
a CR and 9 percent a PR. The median time to remission was 14 weeks (range, 2-55
weeks). Cytogenetic responses were also obtained. Twenty of the 36 responding
patients showed a reduction in the percentage of (Ph')-positive metaphases with five
patients having complete disappearance of all Ph'-positive cells on at least one
examination. Optimal response was achieved at a dose of 5 x 106 U/M2 daily in
lower-risk disease, which they defined as newly diagnosed, previously untreated,
Ph'-positive patients with low to moderately high leukocytosis. Similar therapeutic
results have been reported in four subsequent series. The cytogenetic changes in these
studies, however, were less impressive, apparently because IFN was given in lower
doses [104,107-109]. Unfortunately, toxicity is significant when IFN is given in the
optimal dose schedule of 5 x 106 U/m2/day. Nearly one-third of patients experience
grade 3 toxicities, consisting of cytopenias, hepatitis, and neurological symptoms.
Whether IFN offers long-term therapeutic gain over standard cytotoxic agents to
justify this toxicity is not known. Ongoing phase III trials are comparing IFN to
hydroxyurea. Alpha IFN is also effective in controlling thrombocytosis in CML and
other myeloproliferative disorders [110-113]. IFN activity during the accelerated and
blast phases of CML is minimal with only a minority of patients showing brief
improvement in the hematologic deterioration [106-109].
The efficacy of gamma IFN in CML is under evaluation and preliminary results
suggest that about 25 percent of patients achieve a complete hematologic remission.
Particularly interesting is laboratory work showing a potential synergy between alpha
and gamma IFN [114]. Clinical trials employing combinations of alpha and gamma
IFNs for CML are currently under way. Other investigators are looking at alpha IFN
combined with standard cytotoxic agents such as busulfan for the chronic phase ofthis
disease [1 15].
Lymphomas
Lymphomas are a heterogeneous group oflymphoreticular neoplasms which can be
divided into Hodgkin's disease, non-Hodgkin's lymphoma, and a miscellaneous group
which includes the cutaneous T-cell lymphomas. As shown in Fig. 1, the best results
have been observed in the cutaneous T-cell lymphomas with about 70 percent of
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patients responding to alpha IFN. Responses appear to be dose-related and last from
three months to more than three years [116-119]. Among the non-Hodgkin's group,
IFN is most effective for the low-grade lymphomas with follicular histologies
[120-127]. Efficacy might be further improved if IFN were combined with cytotoxic
drugs [128,129]. Only limited information is available in Hodgkin's disease and the
intermediate and high-grade lymphomas, but they do not appear to be very responsive
to alpha IFN [121,122].
Chronic Lymphocytic Leukemia andAcute Leukemias
Alpha IFN exhibits antitumor activity in about 20 percent of patients with chronic
lymphocytic leukemia (CLL) but remissions are usually partial and short-lived
[121,125,127,130-133]. Early-stage disease is most likely to respond but hematologic
improvement is not sustained once IFN is withdrawn [134]. IFN has also very limited
activity as induction therapy in the acute leukemias [135-139]. One randomized
study, however, suggests that alpha IFN administered after marrow transplantation
for acute lymphocytic leukemia may reduce the risk of leukemic relapse [140]. This
interesting finding warrants further evaluation.
Multiple Myeloma
Using a 50 percent or greater reduction in the myeloma immunoglobulin as response
criteria, about 20 percent of both untreated and refractory myeloma patients achieve
remissions with alpha IFN [111,117,141-149]. The median duration of response to
IFN ranges from two to more than 14 months, with approximately one-third of the
patients having remissions lasting more than one year [141-144]. Although the
activity of IFN as a single agent is modest in multiple myeloma (MM), recent studies
suggest that IFN may play a more important role when used sequentially or in
combination with cytotoxic agents. The Myeloma Group of Central Sweden recently
reported a randomized trial showing a higher response rate (82 percent vs. 52 percent,
p < 0.01) and a lower disease progression (4 percent vs. 21 percent) when alpha IFN
was combined with melphalan/prednisone than when this chemotherapy regimen was
used alone [150]. IFN may also be useful as maintenance therapy in this disease. In
patients who had responded to induction chemotherapy, preliminary results of a
multi-center trial have shown significantly longer remission durations in a group of
patients randomized to maintenance alpha IFN until relapse compared with control
[151]. It is not yet known whether prolongation of remission will translate into a
survival advantage.
EXPERIENCE IN SOLID TUMORS
In contrast to the hematologic malignancies, IFN activity in solid tumors is much
more modest (Fig. 2). The highest response rate has been observed in epidemic
Kaposi's sarcoma (EKS) [152-159]. Alpha IFN has recently received FDA approval
for treatment of EKS. Indications for treatment include pulmonary KS, rapidly
progressive cutaneous disease, or symptomatic visceral involvement. Higher doses of
IFN produce better response rates [157]. At the recommended doseof3 x 106 U daily,
alpha IFN produces tumor regression in 30-40 percent of treated patients. Factors
predictive of improved response include: the absence of a previous opportunistic
infection, lack of systemic symptoms (fever, sweats, weight loss), and relative
immunological competence as measured by the number of circulating CD4 lympho-
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cytes and intact skin testing for delayed hypersensitivity. In this subset ofpatients, the
overall response rate exceeds 50 percent [158,159]. Toxicity is significant, however,
with up to a third of patients requiring dose reduction because of asthenia or
neutropenia [156]. Equivalent response rates can be obtained with several cytotoxic
regimens, but some of these agents produce prolonged myelosuppression and the
development ofopportunistic infections has been observed. Combinations of IFN with
cytotoxic drugs are probably no more efficacious at the cost of increased side effects.
IFN's activity in this disease may be due in part to a direct anti-retroviral effect
[1a60,161, and current studies are evaluating the combination of IFN with AZT.
Phase I trials ofgamma IFN have failed to show significant antitumor effect. Based on
in vitro data, very low-dose gamma IFN alone, or in combination with othercytokines,
is currently being investigated [71859].
Of the solid tumors, renal cell carcinoma (RCC) and malignant melanoma have
been the most amply studied [1i62-181. While the overall response rate does not
exceed 20 percent in either melanoma (MEL) or renal cancer, alpha IFN is one ofthe
few standard agents with definite and reproducible antitumor activity in thesediseases.
An occasional patient will experience a sustained remission [164,167,180]. The role of
IFN as adjuvant therapy following resection of localized disease is currently being
studied in both ofthese malignancies.
Response rates of 20 percent to systemically administered IFN have also been
reported in brain tumors [117,182-186]. This estimate ofactivity is based, however, on
small series which included patients just completing treatment with radiation or
surgery, making assessment ofobjective responses difficult. Alpha IFN is a clinically
useful drug in malignant endocrine tumors. Although the objective response is low, 40
percent to 50 percent of patients treated experience subjective improvement in
endocrine-related symptoms and have more than a 50 percent reduction in the
biologically active peptides [78,187-190].
For ovarian, bladder, head and neck, and cervix cancers, systemic administration of
IFNs has largely proven ineffective [117,191-200]. Preliminary evidence, however,
suggests that IFN may be synergistic when used with cytotoxic drugs [201].
Locoregional or intralesional administration of IFN also appears promising, and
larger-scale studies will be needed to assess the merits of these modalities (Fig. 3).
Relapsed ovarian cancer is frequently confined to theperitoneal cavity and intraperito-
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neal (IP) administration of IFN reaches peak concentrations up to 3 logs greater than
those obtainable in plasma. Locoregional therapy for ovarian cancer has been reported
in one series of 14 patients [202]. All had a positive second-look laparotomy following
combination chemotherapy and received IP IFN at the maximally tolerated dose of
50 x 106 U/M2 per week for 16 consecutive weeks. After completion of therapy, 11
patients were surgically restaged. Five responses were noted, with four patients
attaining a complete remission. These four patients all had non-bulky disease at the
start of the trial, suggesting that alpha IFN may be most effective in the setting of
minimal residual disease. Phase I trials evaluating IP beta and gamma IFN have also
been conducted. In one trial, four of seven patients with advanced refractory disease
showed a clinical response to beta IFN [203]. Results with IP gamma IFN have been
less promising [204].
Carcinoma of the bladder presents as superficial disease in 80 percent of patients.
Following transurethral resection, 50 percent of these patients will have a recurrence.
Patients with high-grade lesions, multiple recurrences, invasion ofthe submucosa, and
carcinoma in situ (CIS) are candidates for intravesicular therapy. Several agents
including cytotoxic drugs and bacillus Calmette-Guerin (BCG) have shown activity in
these settings. With these agents, responses in superficial transitional cell carcinoma
(TCC) and CIS have ranged from 20-60 percent. Following resection, the recurrence
rate of TCC is decreased from 45 percent to 15-20 percent if prophylactic BCG is
given [205]. Intravesicular alpha IFN is as effective as standard agents and is less toxic
[206]. The optimal dose and duration of therapy of intravesicular IFN is currently
under investigation.
In non-melanomatous skin cancers, intralesionally injected alpha IFN exhibits
marked antitumor activity. In one series ofeight patients with basal cell carcinoma, all
achieved a pathologic CR [207]. In 17 patients with squamous and basal cell
carcinoma, subsequent resection showed no residual disease in 13 [208]. IFN may be
an alternative tosurgery in thesediseases and in somecases provide a superior cosmetic
result.
Intra- or perilesional injections of IFNs have also been employed in some head and
neck cancers, in locally advanced carcinoma of the cervix, and in brain tumors. No
conclusions in regard to efficacy can be made because of the small numbers treated
[208-212]. Some activity, however, has been shown, and multi-center trials are under
280INTERFERONS IN MALIGNANT NEOPLASMS 281
way. Unfortunately, IFNs have little or no activity in the more common solid tumors
such as breast [213-220], lung [221-225], colon [81,226-231], stomach [117,232],
and prostate cancer [233,234]. Osteosarcoma, soft tissue sarcomas, and hepatoma are
also usually refractory to IFN therapy [187,232,235].
SUMMARY
Intensive trials have defined the activity of alpha IFN and the maximal tolerated
dose. This information is still being accumulated for beta and gamma IFN. Despite
early optimism, the IFNs have not proven to be a panacea for cancer treatment. No
tumor has been rendered curablewith the IFNs, and the most common neoplasms have
sadly proved exceedingly resistant. The current clinical significance ofthe IFNs belies
their importance in oncology: IFNs represent the first class of cytokines isolated and
placed in clinical trials.
IFN's antitumor effect is reproducible in several hematologic malignancies but only
in a handful ofsolid tumors. IFN is a clear advance in the treatment ofHCL, but even
this indication is jeopardized by pentostatin. In myeloma, maintenance therapy with
IFN enhances the durability ofremission and may result in improved survival. For the
chronic phase of CML, IFN as a single agent or in combination with cytotoxic drugs
may prove to be superior to cytotoxic agents alone.
In responsive solid tumors, IFN seems to be most active in the setting of minimal
residual disease. Clinical trials are currently examining IFN as an adjuvant therapy
following surgical resection of high-risk melanoma and renal cell carcinoma. IFN is
also active as a local therapy in several malignancies, including superficial bladder
cancer and locally advanced ovarian carcinoma. It is too early to determine what role
IFN will have in the management ofthese diseases.
Comprehension ofthe role ofthe IFNs and other cytokines in the complex function
of the immune system remains in its infancy. Early data suggest that IFN used in
combination with other biologicals or cytotoxic drugs is more effective than when it is
used as monotherapy. As the physiological role of IFN and other cytokines is
eventually elucidated, more rational strategies to employ biological proteins in cancer
treatment will be designed.
REFERENCES
1. Isaacs A, Lindemann J: Virus interference. The interferon. Proc R Soc B 147:258-267, 1957
2. Shearer M, Taylor-Papadimitriou J: Regulation ofcell growth by interferon. Cancer Metastasis Rev
6:199-221, 1987
3. Pestka S, LangerJA: Interferon and their actions. Ann Rev Biochem 56:727-777, 1987
4. Borden EC: Progress toward therapeutic applicationofinterferons, 1979-1983. Cancer 54:2770-2776,
1984
5. Branca AA, Baglioni C: Binding to human cells of ['251] labelled alpha interferon produced in E. coli.
Evidence for distinct receptors for type I and II interferons. Nature 294:768-770, 1981
6. Epstein LB: Interferon-gamma: Success, structure and speculation. Nature 295:453-454, 1982
7. Littman SJ, Faltynek CR, Baglioni C: Binding of human recombinant '25I-interferon gamma to
receptor on human cells. J Biol Chem 260:1191-1195, 1985
8. Strander H, Cantell K, Carlstrom G, Jakobsson PA: Clinical and laboratory investigations on man:
Systemic administration ofpotent interferon to man. JNCI 51:733-742, 1973
9. Johnson MD: Sources of interferon for clinical use: Alpha interferons from human lymphoblastoid
cells. In Interferon. Volume 4: In Vivo and Clinical Studies. Edited by NB Finter, RK Oldham.
Amsterdam, Elsevier Science Publisher BV, 1985, pp 81-87
10. Finter NB, Strander HA: Human lymphoblastoid interferon: A clinical update. Med Clin N Amer
70:3 (Supplement) 1-6, 1986282 MURREN AND BUZAID
11. Content J: The antiviral effect of interferon on cells. In Interferon 1: General and Applied Aspects.
Edited by A Billiau. Amsterdam, Elsevier Science Publisher BV, 1984, pp 125-138
12. Gresser I: How does interferon inhibit tumor growth? Interferon 6:93-123, 1985
13. De Maeyer-Guignard J, DeMaeyer E: Immunomodulation by interferons: Recent developments.
Interferon 6:69-86, 1985
14. Balkwill FR: The regulatory role of interferons in the human immune response. In Interferons: Their
Impact in Biology and Medicine. Edited by J Taylor-Papadimitriou. New York, Oxford University
Press, 1985, pp 61-80
15. Chen BDM, Najor F: Macrophageactivation by interferon a + B associated with a lossofproliferative
capacity: Role of interferon a + B in the regulation of macrophage proliferation and function. Cell
Immunol 106:343-354, 1987
16. Brouty-Boye D: Interferon and the tumor cell phenotype. Interferon 7:145-163, 1986
17. Jonak GJ, Knight E Jr: Interferons and the regulation ofoncogenes. Interferon 7:167-180, 1986
18. Rossi GB: Interferons and cell differentiation. Interferon 6:31-62, 1985
19. Clemens MJ, McNurlan MA: Regulation of cell proliferation and differentiation by interferons.
Biochem J 226:345-360, 1985
20. Balkwill FR: Interferons: From molecular biology to man. Part I, genetics and molecular biologyofthe
interferon system. Microbiol Sci 3:212-215, 1986
21. Johnston MI, Torrence PF: The role of interferon-induced proteins, double-stranded RNA and 2',
5'-oligoadenylate in the interferon-mediated inhibition of viral translation. In Interferon 3: Mecha-
nismsofProduction and Action. Edited by RM Friedman. Amsterdam, ElsevierScience Publisher BV,
1984, pp 189-298
22. Roberts WK, Hovanessian A, Brown RE, Clemens MJ, Kerr IM: Interferon-mediated protein kinase
and low-molecular-weight inhibitor ofprotein synthesis. Nature 264:477-480, 1976
23. Sekar V, Atmar V, Krim M, Kuehn GD: Interferon induction ofpolyamine-dependent protein kinase
activity in Ehrlich ascites tumor cells. Biochem Biophys Res Commun 106:305-311, 1982
24. Steis RG, Smith JW, Urba WJ, et al: Resistance to recombinant interferon alfa-2a in hairy cell
leukemia associated with neutralizing anti-interferon antibodies. N Engl J Med 318:1409-1413,
1988
25. Toy J: The interferons. Clin Exp Immunol 54:1-13, 1983
26. Pegg AE, McCann PP: Polyamine metabolism and function. Am J Physiol 243:212-221, 1982
27. Clemens M: Interferons and oncogenes. Nature 313:531-532, 1985
28. Tumarkin L, Masibay A, Damewood GP IV, Sreevalsan T: Interferon mediated regulation of gene
expression in mouse cells. In Interferons as Cell Growth Inhibitors and Antitumor Factors. Edited by
RM Friedman, T Merigan, T Sreevalsan. New York, Alan R Liss Inc, 1986, pp 151-171
29. Samuel CE, Silverman RH: Workshop summary: Gene regulation and differentiation. In Interferons
as Cell Growth Inhibitors and Antitumor Factors. Edited by RM Friedman, T Merigan, TSreevalsan.
New York, Alan R Liss Inc, 1986, pp 139-142
30. Brouty-Boye D, Wybier-Franqui J, Suarez HG: IFN-induced phenotypic changes in human tumor
cells relative to theeffect ofIFN on oncogene expression. In Interferons as Cell Growth Inhibitors and
Antitumor Factors. Edited by RM Friedman, T Merigan, T Sreevalsan. New York, Alan R Liss Inc,
1986, pp 309-317
31. Herberman RB,Thurman GB: Approaches totheimmunological monitoringofcancerpatients treated
with natural or recombinant interferons. J Biol Resp Modif 2:548-562, 1983
32. Teichmann JV, Sieber G, Ludwig W, Ruehl H: Immunosuppressive effects ofrecombinant interferon-
a during long-term infusion ofcancer patients. Cancer 63:1990-1993, 1989
33. Silver HKB, Connors JM, Kong S, Karim KA, Spinelli JJ: Survival, response and immune effects in a
prospectively randomized study of dose strategy for alpha-NI interferon. Br J Cancer 58:783-787,
1988
34. Edwards BS, Merritt JA, Fuhlbridge RC, Borden EC: Low doses of interferon alpha result in more
effective clinical natural killer cell activation. J Clin Invest 75:1908-1913, 1985
35. Spina CA, Fahey JL, Durkos-Smith D, Dorey F, Sarna G: Suppression of natural killer cell
cytotoxicity in the peripheral blood of patients receiving interferon therapy. J. Biol Resp Modit
2:428-440, 1983
36. Goldstein D, Laszlo J: Interferon therapy in cancer: From imaginon to interferon. Cancer Res
46:4315-4329, 1986
37. Strander HA: Interferon in the treatment of human papilloma virus. Med Clin N Amer 70
(Supplement):19-23, 1986INTERFERONS IN MALIGNANT NEOPLASMS 283
38. Salmon SE, Durie BGM, Young L, Liu RM, Trown PW, Stebbing N: Effects of cloned human
leukocyte interferons in the human tumor stem cell assay. J Clin Oncol 1:217-225, 1983
39. Balkwill FR, Smyth JF: Interferons in cancer therapy; A reappraisal. Lancet ii:317-319, 1987
40. Sigaux F, Castaigne S, Lehn P, et al: Alpha interferon on hairy cell: Differentiation or cytotoxicity?
(Abstract). 4th Int Symp on Therapy ofAcute Leukemias, February 7-12, 1987. Rome, Italy, p 253
41. Paganelli KA, Evans SS, Han T, Ozer H: B cell growth factor-induced proliferation of hairy cell
lymphocytes and inhibition by type I interferon in vitro. Blood 67:937-942, 1986
42. Yoffe G, Blick M, Kantargian H, Spritzer G, Gutterman J, Talpaz M: Molecular analysis of
interferon-induced suppression of Philadelphia chromosome in patients with chronic myeloid leuke-
mia. Blood 69:961-963,1987
43. Hawkins MJ, Borden EC, Merritt JA, et al: Comparison of the biologic effects of two recombinant
human interferons alpha (rA and rD) in humans. J Clin Oncol 2:221-226, 1984
44. Nathan CF, Horowitz CR, De La Harpe J, et al: Administration ofrecombinant interferon-^y tocancer
patients enhances monocyte secretion of hydrogen peroxide. Proc Natl Acad Sci USA 82:8686-8690,
1985
45. Balmer CM: The new alpha interferons. Drug Intell Clin Pharm 19:887-893, 1985
46. Gutterman JU, Fine S, Quesada J, et al: Recombinant leukocyte A interferon: Pharmacokinetics,
single-dose tolerance, and biologic effects in cancer patients. Ann Int Med 96:549-556, 1982
47. Merigan TC: Pharmacokinetics and sideeffects ofinterferon in man.Texas Rep Biol Med 35:541-547,
1977
48. Bocci V: Distribution, catabolism and pharmacokinetics of interferons. In Interferon, Volume 4: In
Vivoand Clinical Studies. Edited byNB Finter, RK Oldham. Amsterdam, Elsevier Science Publishers
BV, 1985, pp 47-72
49. MartinoS: Serial interferon alpha 2 levels in serum and cerebrospinal fluid (Letter). Cancer Treat Rep
68:1057-1058, 1984
50. Smith RA, Norris F, Palmer D, Berhardt L, Wills RJ: Distribution ofalpha interferon in serum and
cerebrospinal fluid after systemic administration. Clin Pharmacol 37:85-88, 1985
51. Sarna G, Figlin R, Bryson Y, et al: Human a-lymphoblastoid interferon. Am J. Clin Oncol (CCT)
8:406-412, 1985
52. Bocci V: Catabolism and toxicity ofinterferons. Drugs Exptl Clin Res 7:683-689, 1982
53. Bino T, Madar Z, Gertler A, Rosenberg H: The kidney is the main site of interferon degradation. J
InterfRes 2:301-314, 1982
54. Hirsch MS, Tolkoff-Rubin NE, Kelly AP, Rubin RH: Pharmacokinetics of human and recombinant
leukocyte interferon in patients with chronic renal failure who are undergoing hemodialysis. J Infect
Dis 148:335, 1983
55. Shah I, Band J, Samson M, et al: Pharmacokinetics and tolerance of intravenous and intramuscular
recombinant alpha 2 interferon in patients with malignancies. Am J Hematol 17:363-371, 1984
56. Jones GJ, Itri LM: Safety and tolerance of recombinant interferon a-2a(Roferon@-A) in cancer
patients. Cancer 57:1709-1715, 1986
57. Spiegel RJ: The alpha interferons: Clinical overview. Semin Oncol 14(Supplement 2):1-12, 1987
58. Quesada JR, Talpaz M, Rios A, Kurzrock R, Gutterman JU: Clinical toxicity ofinterferons in cancer
patients: A review. J Clin Oncol 4:234-243,1986
59. Rinehart J, Malspeis L, Young D, Neidhart J: Phase I/II trial of human recombinant B-interferon
serine in patients with renal carcinoma. Cancer Res 46:5364-5367, 1986
60. Hawkins M, Horning S, Konard M, et al: Phase I evaluation of a synthetic mutant of B-interferon.
Cancer Res 45:5914-5920, 1985
61. Vadhan-Raj S, Al-Katib A, Bhalla R, et al: Phase I trial of recombinant interferon gamma in cancer
patients. J Clin Oncol 4:137-146, 1986
62. Kurzrock R, Quesada JR, Talpaz M, et al: Phase I study of multiple dose intramuscularly
administered recombinant gamma interferon. J Clin Oncol 4:1101-1109, 1986
63. Thompson JA, Cox WW, Lindgren CG, et al: Subcutaneous recombinant gamma interferon in cancer
patients: Toxicity, pharmacokinetics, and immunomodulatory effects. Cancer Immunol Immunother
25:47-53, 1987
64. Rohatiner AZS, Prior PF, Burton AC, Smith AT, Balkwill FR, Lister TA: Central nervous system
toxicity ofinterferon. Br J Cancer 47:419-422,1983
65. Smedley H, Katrak M, Sikora K, Wheeler T: Neurological effects of recombinant human interferon.
Br Med J 286:262-264, 1983284 MURREN AND BUZAID
66. Mattson K, Niiranen A, Iivanainen M, et al: Neurotoxicity of interferon. Cancer Treat Rep
67:958-961, 1983
67. Ernstoff MS, Kirkwood JM: Changes in the bone marrow ofcancer patients treated with recombinant
interferon alpha-2. Am J Med 76:593-596, 1984
68. Akard LP, Hoffman R, Elias L, Saiers JH: Alpha-interferon and immune hemolytic anemia (Letter).
Ann Int Med 105:306, 1986
69. McLaughlin P, Talpaz M, Quesada JR, Saleem A, Barlogie B, Gutterman J:Immune thrombocytope-
nia following a-interferon therapy in patients with cancer. JAMA 254:1353-1354, 1985
70. Mirro J Jr, Kalwinsky D, Whisnant J, Weck P, Chesney C, Murphy S: Coagulopathy induced by
continuous infusion ofhigh doses ofhuman lymphoblastoid interferon. Cancer Treat Rep 69:315-317,
1985
71. Abdi EA, Brien W, Venner PM: Auto-immune thrombocytopenia related to interferon therapy. Scand
J Haematol 36:515-519,1986
72. Selby P, Kohn J, Raymond J, Judson I, McElwain T: Nephrotic syndrome during treatment with
interferon. Br Med J 290:1180, 1985
73. Averbuch SD, Austin HA III, Sherwin SA, Antonovych T, Bunn PA Jr, Longo DL: Acute interstitial
nephritis with nephrotic syndrome following recombinant leukocyte A interferon therapy for mycosis
fungoides. N Engl J Med 310:32-35,1984
74. Foon KA, Dougher G: Increased growth ofeyelashes ina patientgiven leukocyte A interferon (Letter).
N Engl J Med 311:1259, 1984
75. Fentiman IS, Thomas BS, Balkwill FR, Rubens RD, Hayward JL: Primary hypothyroidism associated
with interferon therapy ofbreast cancer (Letter). Lancet i:1166, 1985
76. Burman P, Karlsson FA, Oberg K, Alm G: Autoimmune thyroid disease in interferon-treated patients
(Letter). Lancet ii:100-101, 1985
77. Bevan PC: Interferon-induced parotitis and epididymitis (Letter). Lancet ii:1297-1304, 1985
78. Oberg K, Norheim I, Lind E, et al: Treatment of malignant carcinoid tumors with human leukocyte
interferon: Long term results. Cancer Treat Rep 70:1297-1304, 1986
79. Burman P, Totterman TH, Oberg K, Karlsson FA: Thyroid autoimmunity in patients on long term
therapy with leukocyte-derived interferon. J Clin Endocrinol Metab 63:1086-1090, 1986
80. Mannering G: Measurement ofeffect of interferon on drug metabolism. Methods Enzymol 119:718-
725, 1986
81. Krown SE, Mintzer D, Cunningham-Rundles S, et al: High-dose human lymphoblastoid interferon in
metastatic colorectal cancer: Clinical results and modification of biological responses. Cancer Treat
Rep 71:39-45, 1987
82. Von Wussow P, Freund M, Block B, Diedriech H, Poliwoda H, Deicher H: Clinical significance of
anti-IFN-a antibody titres during interferon therapy (Letter). Lancet ii:635-636, 1987
83. Itri LM, Campion M, Dennin RA, et al: Incidence and clinical significance ofneutralizing antibodies
in patients receiving recombinant interferon a-2a by intramuscular injection. Cancer 59 (Supple-
ment):668-674,1987
84. Oberg K, Alm G, Magnusson A, Lundqvist G, Theodorsson E, Wide L, Wilander E: Treatment of
malignant carcinoid tumors with recombinant interferon alfa-2b: Development of neutralizing
interferon antibodies and possible loss ofantitumor effect. JNCI 81:531-535, 1989
85. Quesada JR, Lepe-Zuniga JL, Gutterman JU: Mid-term observations on the efficacy of a-interferon
in hairy cell leukemia and status of the interferon system of patients in remission. Leukemia
1:317-319, 1987
86. Quesada JR, Reuben J, Manning JT, Hersh EM, Gutterman JU: Alpha interferon for induction of
remission in hairy-cell leukemia. N Engl J Med 310:15-18, 1984
87. Thompson JA, Fefer A: Interferon in the treatment of hairy cell leukemia. Cancer 59 (Supple-
ment):605-609, 1987
88. Foon KA, Maluish AE, Abrams PC, et al: Recombinant leukocyte A interferon therapy for advanced
hairy cell leukemia. Am J Med 80:351-356,1986
89. Worman CP, Catovsky D, Bevan PC, et al: Interferon is effective in hairy-cell leukemia. Br J Hematol
60:759-763, 1985
90. Hofmann V, Fehr J, Sauter C, Ottino J: Hairy cell leukemia: An interferon deficient disease? Cancer
Treat Rev 12 (Supplement B):33-37, 1985
91. Mandelli F, Annino L, Cafolla A, et al: Hairy cell leukemia: Preliminary results with alpha 2 (r)
interferon. Tumori 72:153-156, 1986INTERFERONS IN MALIGNANT NEOPLASMS 285
92. Hagberg H, Alm G, Bjorkholm M, et al: Alpha interferon treatment of patients with hairy cell
leukemia. Scand J Hematol 35:66-70, 1985
93. Castaigne S, Sigaux F, Cantell K, et al: Interferon alpha in the treatment of hairy cell leukemia.
Cancer 57:1681-1684, 1986
94. Flandrin G, Sigaux F, Castaigne S, et al: Treatment of hairy cell leukemia with recombinant alpha
interferon: I. Quantitative study of bone marrow changes during first months of treatment. Blood
67:817-820, 1986
95. Worman CP, Catovsky D, Cawley JC, Bevan PC, Bottomly JM, Nethersell ABW: The U.K.
experience with human lymphoblastoid interferon in HCL: A report of the first 50 cases. Leukemia
1:320-322, 1987
96. Glaspy JA, Jacobs AD, Golde DW: The UCLA experience with type I interferons in hairy cell
leukemia. Leukemia 1:323-326, 1987
97. Damasio EE, Bernasconi C, Castoldi G, et al: Human lymphoblastoid interferon for hairy cell
leukemia: Results from the Italian Cooperative Group. Leukemia 1:331-333, 1987
98. Smalley R, Tuttle R, Whisnant J, et al: Effectiveness ofa-n-I at an ultra low dose in the treatment of
hairy cell leukemia (HCL) (Abstract). Proc Am Soc Clin Oncol 6:155, 1987
99. Ratain MJ, Golomb HM, Bardawill RG, et al: Durability ofresponses to interferon a-2b in advanced
hairy cell leukemia, Blood 69:872-877, 1987
100. Golomb HM, Ratain MJ, Fefer A, et al: Randomized study of the duration of treatment with
interferon a-2b in patients with hairy cell leukemia. JNCI 80:369-373, 1988
101. Ratain MJ, Golomb HM, Vardeman JW, et al: Relapse after interferon alfa-2b therapy for hairy cell
leukemia: Analysis ofprognostic variables. J Clin Oncol 6:1714-1721, 1988
102. Samuels BL, Golomb HM, Brownstein BH: Different proteins are induced by alpha- and gamma-
interferon in hairy cell leukemia. J Biol Resp Modif6:268-274, 1987
103. Krant EH, Bouroncle BA, Grever MR: Pentostatin in the treatment ofadvanced hairy cell leukemia. J
Clin Oncol 7:168-172, 1989
104. Oladipupo-Williams CK, Svet Moldavskaya I, Vicek J, et al: Inhibitory effects of human leukocyte
and fibroblast interferons on normal and chronic myelogenous leukemic granulocyte progenitor cells.
Oncology 38:356-360,1981
105. Talpaz M, McCredie KB, Mavligit GM, Gutterman JU: Clinical investigation of human alpha
interferon in chronic myelogenous leukemia. Blood 62:689-692, 1983
106. Talpaz M, Kautarjian HM, McCredie KB, Keating MJ, Trujillo J, Gutterman JU: Clinical
investigation ofhuman alpha interferon in chronic myelogenous leukemia. Blood 69:1280-1288, 1987
107. Niederle N, Kloke 0, Osieka R, Wandl U, Opalka B, Schmidt CG: Interferon a-2b in the treatment of
chronic myelogenous leukemia. Semin Oncol 14 (Supplement 2):29-35, 1987
108. Alimena G, Morra E, Lazzarino M, et al: Interferon alpha-2b as therapy for Ph'-positive chronic
myelogenous leukemia: A study of82 patients treated with intermittent or daily administration. Blood
72:642-647, 1988
109. Gastl G, Aulitzky Q, Tilig H, et al: Dose related effectiveness of alpha interferon in chronic
myelogenous leukemia (Letter). Blut 54:251-252, 1987
110. Talpaz M, Mavligit G, Keating M, Walters RS, Gutterman JU: Human leukocyte interferon to
control thrombocytosis in chronic myelogenous leukemia. Ann Int Med 99:789-792, 1983
111. Ludwig H, Cortelezzi A, Van Camp BGK, et al: Treatment with recombinant-alpha-2C: Multiple
myeloma and thrombocythaemia in myeloproliferative diseases. Oncology 42 (Supplement 1):19-25,
1985
112. Velu T, Delwiche F, Gangji D, et al: Therapeutic effect ofhuman recombinant interferon-alpha-2C in
essential thrombocythaemia. Oncology 42 (Supplement 1):10-14, 1985
113. Lazzarino M, Vitale A, Morra E, et al: Interferon alpha-2b in the treatment of Philadelphia negative
chronic myeloproliferative with excessive thrombocytosis. New Trends Ther Leuk Lymph 2:83-88,
1987
114. Kantarjian HM, Talpaz M, Kurzrock R, et al: Intensive combination chemotherapy and interferons in
the management ofchronic myelogenous leukemia. Acta Haemat 78 (Supplement 1):70-74, 1987
115. Bergsagel DE, Hass RH, Messner HA: Interferon alfa-2b in the treatment of chronic granulocytic
leukemia. Semin Oncol 13 (Supplement 2):29, 1986
116. Bunn PA Jr, Foon KA, Ihde DC, et al: Recombinant leukocyte A interferon: An active agent in
advanced cutaneous T-cell lymphomas. Ann Int Med 101:484-487, 1984
117. Taguchi T: Clinical studies of recombinant interferon a-2a (Roferon®-A) in cancer patients. Cancer
57:1705-1708, 1986286 MURREN AND BUZAID
118. Olsen E, Rosen S, Vollmer R, Variakojis D, Roenigk H, Zeffren J: Interferon a-2a in the treatment of
cutaneous T-cell lymphoma (Abstract). Proc Am Soc Clin Oncol 6:189, 1987
119. Covelli A, Cavalieri R, Coppola G, et al: Recombinant leukocyte interferon (IFL-rA) as initial therapy
in mycosis fungoides (MF) and Sezary Syndrome (SS) (Abstract). Proc Am Soc Clin Oncol 6:189,
1987
120. Foon KA, Sherwin SA, Abrams PG, et al: Treatment of advanced non-Hodgkin's lymphoma with
recombinant leukocyte A interferon. N Engl J Med 311:1148-1152, 1984
121. Horning SJ, Merigan TC, Krown SE, et al: Human interferon alpha in malignant lymphoma and
Hodgkin's disease. Results ofthe American Cancer Society trial. Cancer 56:1305-1310, 1985
122. Leavitt RD, Ratanatharathorn V, Ozor H, et al: a-2b interferon in the treatment ofHodgkin's disease
and non-Hodgkin's lymphoma. Semin Oncol 14 (Supplement 2):18-23, 1987
123. Wagstaff J, Loynds P, Crowther D: A phase II study of human rDNA alpha-2 interferon in patients
with low grade non-Hodgkin's lymphoma. Cancer Chemother Pharmacol 18:54-58, 1986
124. Louie AC, Gallagher JG, Sikora K, Levy R, Rosenberg SA, Merigan TC: Follow-up observations on
the effect ofhuman leukocyte interferon in non-Hodgkin's lymphoma. Blood 58:712-718, 1981
125. O'Connel MJ, Colgan JP, Oken MM, Ritts RE Jr, Kay NE, Itri M: Clinical trial of recombinant
leukocyte A interferon as initial therapy for favorable history non-Hodgkin's lymphomas and chronic
lymphocytic leukemia. An Eastern Cooperative Group pilot study. J Clin Oncol 4:128-136, 1986
126. Quesada JR, Hawkins M, Horning S, et al: Collaborative phase I-II study of recombinant
DNA-produced leukocyte interferon (clone A) in metastatic breast cancer, malignant lymphoma, and
multiple myeloma. Am J Med 77:427-432, 1984
127. Gutterman JU, Blumenschein GR, Alexanian R, et al: Leukocyte interferon-induced tumor regression
in human metastatic breast cancer, multiple myeloma, and malignant lymphoma. Ann Int Med
93:399-406, 1980
128. Chisesi T, Capnist G, Vespignani M, Cetto G: Interferon a-2b and chlorambucil in the treatment of
non-Hodgkin's lymphoma. Invest New Drugs 5 (Supplement):35-40, 1987
129. Ozer H, Anderson JR, Budman DR, et al: Combination trial ofsubcutaneous interferon a-2b and oral
cyclophosphamide in favorable histology, non-Hodgkin's lymphoma. Invest New Drugs 5 (Supple-
ment):27-33, 1987
130. Schulof RS, Lloyd MJ, Stallings JJ, et al: Recombinant leukocyte A interferon in B cell chronic
lymphocytic leukemia: In vivo effects on autologous antitumor activity. J Biol Resp Modif4:310-323,
1985
131. Misset JL, MatheG, Gastiaburu J, et al: Treatmentoflymphoid neoplasias with interferon. II. Human
leukocyte a-interferon in chronic lymphatic leukemia (CLL). Phase I-II trial. Anticancer Res
2:67-70, 1982
132. Foon KA, Bottino GC, Abrams PG, et al: Phase II trial of recombinant leukocyte A interferon in
patients with advanced chronic lymphocytic leukemia. Am J Med 78:216-220, 1985
133. Talpaz M, Rosenblum M, Kurzrock R, Reuben J, Kantarjian H, Gutterman JU: Clinical and
laboratory changes induced by alpha interferon in chronic lymphocytic leukemia. A pilot study. Am J
Hematol 24:341-350, 1987
134. Rozman C, Montserrat E, Vinolas N, et al: Recombinant alpha 2 interferon in the treatment of B
chronic lymphocytic leukemia in early stages. Blood 71:1295-1298, 1988
135. Hill NO, Pardue A, Khan A, Aleman C, Hilario R, Hill JM: Human leukocyte interferon trials in
leukemia and cancer. Drugs Exptl Clin Res 8:677-682, 1982
136. Mirro J, Dow LW, Kalwinsky DK, et al: Phase I-II study of continuous-infusion high-dose human
lymphoblastoid interferon and the in vitro sensitivity of leukemic progenitors in nonlymphocytic
leukemia. Cancer Treat Rep 70:363-367, 1986
137. Rohatiner AZS, Balkwill FR, Malpas JS, Lister TA: Experience with human lymphoblastoid
interferon in acute myelogenous leukemia (AML). Cancer Chemother Pharmacol 11:56-58, 1983
138. Ochs J, Abromowitch M, Rudnick S, Murphy SB: Phase I-II study ofrecombinant alpha-2 interferon
against advanced leukemia and lymphoma in children. J Clin Oncol 4:883-887, 1986
139. Freedman MH, Estrov Z, Williams BRG, Gelfand EW: Clinical and in vitro antiproliferative
properties of recombinant DNA-derived human interferon-a2. Am J Pediatr Hematol Oncol 8:178-
182, 1986
140. Meyers JD, Flournoy N, Sanders JE, et al: Prophylactic use of human leukocyte interferon after
allogeneic marrow transplantation. Ann Int Med 107:809-816, 1987
141. Quesada JR, Alexanian R, Hawkins M, et al: Treatment of multiple myeloma with recombinant
a-interferon. Blood 67:275-278, 1986INTERFERONS IN MALIGNANT NEOPLASMS 287
142. Costanzi JJ, Cooper MR, Scarffe JH, et al: Phase II study of recombinant alpha-2 interferon in
resistant multiple myeloma. J Clin Oncol 3:654-659, 1985
143. Case DC Jr, Sonneborn HL, Paul SD, et al: Phase II studyofrDNA alpha-2 interferon (INTRON A)
in patients with multiple myeloma utilizing an escalating induction phase. Cancer Treat Rep
70:1251-1254, 1986
144. Ohno R, Kimura K, Amaki I, et al: Treatment of multiple myeloma with recombinant human
leukocyte A interferon. Cancer Treat Rep 69:1433-1435, 1985
145. Mellstedt H, Ahre A, Bjorkholm M, Holm G, Johansson B, Strander H: Interferon therapy in
myelomatosis. Lancet i:245-247, 1979
146. Ohno R, Kodera Y, Ogura M, et al: Treatment ofplasma cell neoplasm with recombinant leukocyte A
interferon and human lymphoblastoid interferon. Cancer Chemother Pharmacol 14:34-37, 1985
147. Wagstaff J, Loynds P, Scarffe JH: Phase II study of rDNA human alpha-2 interferon in multiple
myeloma. Cancer Treat Rep 69:495-498, 1985
148. Alexian R, Gutterman J, Levy H: Interferon treatment for multiple myeloma. Clin Hematol
11:211-220, 1982
149. Ahre A, Bjorkholm M, Mellstedt H, et al: Human leukocyte interferon and intermittent high-dose
melphalan-prednisone administration in the treatment of multiple myeloma: A randomized clinical
trial from the Myeloma Group ofCentral Sweden. Cancer Treat Rep 68:1331-1338, 1984
150. Cooper MR: Interferons in the management of multiple myeloma. Semin Oncol 15 (Supplement
5):21-25, 1988
151. Tribalto M, Mandelli F, Cantonetti M, et al: Recombinant alpha 2b interferon as post maintenance
therapy for responding multiple myeloma. Clinical results of a multicentric trial. New Trends Ther
Leuk Lymph 2:61-68, 1987
152. Volberding PA, Mitsuyasu RT, Golando JP, Spiegel RJ: Treatment of Kaposi's sarcoma with
interferon a-2b (Intron A). Cancer 59 (Supplement):620-625, 1987
153. Oettgen HF, Real FX, Krown SE: Treatment ofAIDS-associated Kaposi's sarcoma with recombinant
alpha interferon. Immunobiol 172:269-274, 1986
154. Rios A, Mansell PWA, Newell GR, Reuben JM, Hersh EM, Gutterman JU: Treatment of acquired
immunodeficiency syndrome-related Kaposi's sarcoma with lymphoblastoid interferon. J Clin Oncol
3:506-512, 1985
155. Gelmann EP, Preble OT, Steis R, et al: Human lymphoblastoid interferon treatment of Kaposi's
sarcoma in the acquired immunedeficiency syndrome. Clinical and prognostic parameters. Am J Med
78:737-741, 1985
156. Krown SE: The role of interferon in the therapy of epidemic Kaposi's sarcoma. Semin Oncol 14
(Supplement 3):27-33, 1987
157. Groopman JE, Gottlieb MS, Goodman J, et al: Recombinant alpha-2 interferon therapy for Kaposi's
sarcoma associated with acquired immunedeficiency syndroms. Ann Int Med 100:671-676, 1984
158. Vadhan-Raj J, WongG,GreccoC, etal: Immunological variables aspredictors ofprognosis in patients
with Kaposi's sarcoma and the acquired immunodeficiency syndrome. Cancer Res 46:417-425, 1986
159. Mitsuyasu RT: Kaposi's sarcoma in the acquired immunodeficiency syndrome. In The Medical
Management of AIDS. Edited by MA Sande, P Volberding. Philadelphia, WB Saunders Company,
1988, pp 291-305
160. Lane HC, Kovac JA, Feinberg J, et al: Anti-retroviral effects ofinterferon-alpha in AIDS-associated
Kaposi's sarcoma. Lancet ii:1218-1222, 1988
161. DeWit R, Schattenkerk JKME, Boucher CAB, et al: Clinical and virological effects of high-dose
recombinant interferon-alpha in disseminated AIDS-related Kaposi's sarcoma. Lancet ii:1214-1217,
1988
162. Dekernion JB, Sarna G, Figlin R, Lindner A, Smith RB: The treatment of renal cell carcinoma with
human leukocyte alpha-interferon. J Urol 130:1063-1066, 1983
163. Muss HB, Costanzi JJ, Leavitt R, et al: Recombinant a interferon in renal cell carcinoma: A
randomized trial oftwo routes ofadministration. J Clin Oncol 5:286-291, 1987
164. Umeda T, Niijima T: Phase II study of alpha interferon on renal cell carcinoma. Summary of three
collaborative trials. Cancer 58:1231-1235, 1986
165. Quesada JR, Swanson DA, Gutterman JU: Phase II study ofinterferon alpha in metastatic renal-cell
carcinoma: A progress report. J Clin Oncol 3:1086-1092, 1985
166. Quesada JR, Swanson DA, Trindada A, Gutterman JU: Renal cell carcinoma: Antitumor effects of
leukocyte interferon. Cancer Res 43:940-947, 1983288 MURREN AND BUZAID
167. Buzaid AC, Robertone A, Kisala C, Salmon SE: Phase II study of interferon a-2a, recombinant
(Roferon-A) in metastatic renal cell carcinoma. J Clin Oncol 5:1083-1089, 1987
168. Vugrin D, Hood L, Taylor W, Laszlo J: Phase II study ofhuman lymphoblastoid interferon in patients
with advanced renal carcinoma. Cancer Treat Rep 69:817-820, 1985
169. Edsmyr F, Esposito PL, Andersson L, Steineck G, Lagergren C, Strander H: Interferon therapy in
disseminated renal cell carcinoma. Radiother Oncol 4:21-26, 1985
170. Kirkwood JM, Harris JE, Vera R, et al: A randomized study of low and high doses of leukocyte
a-interferon in metastatic renal cell carcinoma: The American Cancer Society collaborative trial.
Cancer Res 45:863-871, 1985
171. Quesada JR, Rios A, Swanson D, Trown P, Gutterman JU: Antitumor activityofrecombinant-derived
interferon alpha in metastatic renal cell carcinoma. J. Clin Oncol 3:1522-1528, 1985
172. Creagan ET, Ahmann DL, Frytak S, Long HJ, Chang MN, Itri LM: Three consecutive phase II
studies of recombinant interferon a-2a in advanced malignant melanoma. Cancer 59 (Supple-
ment):638-646, 1987
173. Kirkwood JM, Ernstoff MS, Davis CA, Reiss M, Ferraresi R, Rudnick SA: Comparison of
intramuscular and intravenous recombinant alpha-2-interferon in melanoma and other cancers. Ann
Int Med 103:32-36, 1985
174. Robinson WA, Mughal TI, Thomas MR, Johnson M, Spiegal RJ: Treatment ofmetastatic malignant
melanoma with recombinant interferon alpha 2. Immunobiol 172:275-282, 1986
175. Dorval T, Palangie T, Jouve M, et al: Clinical phase II trial of recombinant DNA interferon
(interferon a 2b) in patients with metastatic malignant melanoma. Cancer 58:215-218, 1986
176. Legha SS, Papadopoulos NEJ, Plager C, et al: Clinical evaluation of recombinant interferon a-2a
(Roferon-A) in metastatic melanoma using two different schedules. J Clin Oncol 5:1240-1246, 1987
177. Hersey P, MacDonald M, Hall C, et al: Immunological effects of recombinant interferon a-2a in
patients with disseminated melanoma. Cancer 57:1666-1674, 1986
178. Krown SE, Burk MW, Kirkwood JM, Kerr D, Morton DL, Oettgen HF: Human leukocyte (alpha)
interferon in metastatic malignant melanoma: The American Cancer Society Phase II trial. Cancer
Treat Rep 68:723-726, 1984
179. Retsas S, Priestman TJ, Newton KA, Westbury G: Evaluation ofhuman lymphoblastoid interferon in
advanced malignant melanoma. Cancer 51:273-276, 1983
180. Goldberg RM, Ayoob M, Silgals R, Ahlgren JD, Neefe JR: Phase II trial oflymphoblastoid interferon
in metastatic melanoma. Cancer Treat Rep 69:813-816, 1985
181. Coates A, Rallings M, Hersey P, Swanson C: Phase II study ofrecombinanta2-interferon in advanced
malignant melanoma. J Interferon Res 6:1-4, 1986
182. Anonymous: A phase II studyofrecombinant leukocyte A interferon (RO 22-8181) in malignant brain
tumors. Gan To Kagaku Ryoho 12:913-920, 1985
183. Boethius J, Blomgren H, Collins VP, Greitz T, Strander H: The effect of systemic human
interferon-alpha administration to patient with glioblastoma multiforme. Acta Neurochir (Wein)
68:239-251, 1983
184. Mahaley MSJr, Urso MB, Whaley RA, etal: Immunobiology ofprimary intracranial tumors. Part 10:
Therapeutic efficacy of interferon in the treatment of recurrent gliomas. J Neurosurg 63:719-725,
1985
185. Hirakawa K, Ueda S, Nakagawa Y, et al: Effect of human leukocyte interferon on malignant brain
tumors. Cancer 51:1976-1981, 1983
186. Nagai M, Arai T: Clinical effect of interferon in malignant brain tumors. Neurosurg Rev 7:55-64,
1984
187. Sarna G, Figlin R, McCarthy S: Phase I study ofWellferong (human lymphoblastoid a-interferon) as
cancer therapy: Clinical results. J Biol Resp Modif2:187-195, 1983
188. Eriksson B, Oberg K, Alm G, et al: Treatment ofmalignant endocrine pancreatic tumors with human
leukocyte interferon. Lancet ii:1307-1309, 1986
189. Anderson JV, Bloom SR: Treatment ofmalignant endocrine pancreatic tumors with human leukocyte
interferon (Letter). Lancet i:97, 1987
190. Smith DB, Scarffe JH, Wagstaff J, Johnston RJ: Phase II trial of rDNA alpha-2b interferon in
patients with malignant carcinoid tumor. Cancer Treat Rep 71:1265-1266, 1987
191. Kasamatsu T, Ohmi K, Takeuchi S, et al: Clinical study of recombinant interferon alpha-2 (SCH
30500) in advanced gynecological cancer. Gan To Kagaku Ryoho 12:1656-1660, 1985
192. Einhorn N, Cantell K, Einhorn S, Strander H: Human leukocyte interferon therapy for advanced
ovarian carcinoma. Am J Clin Oncol 5:167-172, 1982INTERFERONS IN MALIGNANT NEOPLASMS 289
193. Abdulhay G, DiSaia PJ, Blessing JA, Creasman WT: Human lymphoblastoid interferon in the
treatment of advanced epithelial ovarian malignancies: A Gynecologic Oncology Group study. Am J
Obstet Gynecol 152:418-423, 1985
194. NiloffJM, Knapp RC, Jones G, Schaetzi EM, Bast RC Jr: Recombinant leukocyte alpha interferon in
advanced ovarian carcinoma. Cancer Treat Rep 69:895-896, 1985
195. Freedman RS, Gutterman JU, Wharton JT, Rutledge RN: Leukocyte interferon (IFN a) in patients
with epithelial ovarian carcinoma. J Biol Resp Modif 2:133-138, 1983
196. Scorticatti CH, De La Pena NC, Bellora OG, Mariotto RA, Casabe AR, Comoli R: Systemic
IFN-alpha treatment of multiple bladder papilloma grade I-II patients: Pilot study. J Interferon Res
2:339-343, 1982
197. Kemeny N, Yagoda A, Wang Y, Field K, Wrobleski H, Whitmore W: Randomized trial of standard
therapy with or without Poly I:C in patients with superficial bladder cancer. Cancer 48:2154-2157,
1981
198. Grups GW, Frohmuller HGW, Ackermann R: Can recombinant human a-2 interferon prevent
recurrence ofhigh-grade superficial bladder tumors? Cancer Detect Prev 10:405-409, 1987
199. Connors JM, Andiman WA, Horwath CB, et al: Treatment ofnasopharyngeal carcinoma with human
leukocyte interferon. J Clin Oncol 3:813-817, 1985
200. Miyake H, Horiuchi M, Tagawa K, et al: Recombinant interferon alpha-2 (SCH 30500) in patients
with head and neck cancer. Gan To Kagaku Ryoho 12:1651-1655, 1985
201. Welander CE: Useofinterferon in the treatment ofovarian cancer as a single agent and in combination
with cytotoxic drugs. Cancer 59:617-619, 1987
202. Berek JS, Hacker NF, Lichtenstein A, et al: Intraperitoneal recombinant a-interferon for "salvage"
immunotherapy in stage III epithelial ovarian cancer: A Gynecologic Oncology Study Group study.
Semin Oncol 13 (Supplement 2):61-71, 1986
203. Rambaldi A, Introna M, Colotta F, et al: Intraperitoneal administration of interferon beta in ovarian
cancer patients. Cancer 56:294-301, 1985
204. Markham M, D'Acquisto R, Hakes T, et al: Lack ofefficacy ofrecombinant gamma-interferon (rGI)
administered by the intraperitoneal (IP) route as therapy ofrefractory ovarian carcinoma (ROC). Clin
Res 35:806A, 1987
205. DeKernion JB, Huang M, Lardner A, et al: Management ofsuperficial bladder tumors and carcinoma
in situ with intravesical BCG. J Urol 133:598-601, 1985
206. Torti FM, Shortliffe LD, Williams RD, et al: Alpha-interferon in superficial bladder cancer: A
Northern California Oncology Group study. J Clin Oncol 6:476-483, 1988
207. Greenway HT, Cornell RC, Tanner DJ, Peets E, Bordin GM, Nagi C: Treatment of basal cell
carcinoma with intralesional interferon. J Am Acad Dermatol 15:437-443, 1986
208. Ikic D, Padovan I, Brodarec I, Knezevic M, Soos E: Application of human leukocyte interferon in
patients with tumors ofthe head and neck. Lancet i:1205-1027, 1981
209. Ikic D, Krusic J, Kirhmajer V, et al: Application of human leukocyte interferon in patients with
carcinoma ofthe uterine cervix. Lancet i:1027-1030, 1981
210. Choo YC, Seto WH, Hsu C, et al: Cervical intraepithelial neoplasia treated by perilesional injection of
interferon. Br J Obstet Gynaecol 93:372-379, 1986
211. Krusic J, Maricic V, Chulah B: Influence of human leukocyte interferon on squamous cell carcinoma
of the uterine cervix: Clinical histological and histochemical observations. Dev Oncol 15:253-255,
1984
212. Nakagawa Y, Hirakawa K, Ueda S, et al: Local administration of interferon for malignant brain
tumors. Cancer Treat Rep 67:833-835, 1983
213. Muss HB, Kempf RA, Martino S, et al: A phase II study ofrecombinant a interferon in patients with
recurrent or metastatic breast cancer. J Clin Oncol 2:1012-1016, 1984
214. Nethersell A, Smedley H, Katrak M, Wheeler T, Sikora K: Recombinant interferon in advanced
breast cancer. Br J Cancer 49:615-620, 1984
215. Sarna GP, Figlin RA: Phase II trial of a-lymphoblastoid interferon given weekly as treatment of
advanced breast cancer. Cancer Treat Rep 69:547-549, 1985
216. Laszlo J, Hood L, Cox E, Goodwin B: A randomized trial of low doses ofalpha interferon in patients
with breast cancer. J Biol Resp Modif 5:206-210, 1986
217. Sherwin SA, Mayer D, Ochs JJ, et al: Recombinant leukocyte A interferon in advanced breast cancer.
Results ofa phase II efficacy trial. Ann Int Med 98 (Part I):598-602, 1983
218. Padmanabhan N, Balkwill FR, Bodmer JG, Rubens RD: Recombinant DNA human interferon alpha
2 in advanced breast cancer: A phase II trial. Br J Cancer 51:55-60, 1985290 MURREN AND BUZAID
219. Borden EC, Holland JF, Dao TL, et al: Leukocyte-derived interferon (alpha) in human breast
carcinoma. The American Cancer Society phase II trial. Ann Int Med 97:1-6, 1982
220. Lenzhofer R, Micksche M, Dittrich C, et al: Recombinant human IFN alpha 2 (Rhu-IFN-alpha 2) in
advanced breast cancer. Drugs Exptl Clin Res 10:463-470, 1984
221. Sarna G, Figlin R, Callaghan M: a (human leukocyte)-interferon as treatment for non-small cell
carcinoma ofthe lung: A phase II trial. J Biol Resp Modif 2:343-347, 1983
222. Grunberg SM, Kempf RA, Itri LM, Venturi CL, Boswell WD, Mitchell MS: Phase II study of
recombinant alpha interferon in the treatment of advanced non-small cell lung carcinoma. Cancer
Treat Rep 69:1031-1032, 1985
223. Olesen BK, Ernst P, Nissen MH, Hansen HH: Recombinant interferon A (IFL-rA) therapy of small
cell and squamous cell carcinoma ofthe lung. A phase II study. Eur J Cancer Clin Oncol 23:987-989,
1987
224. Jones DH, Bleehen NM, Slater AJ, George PJM, Walker JR, Dixon AK: Human lymphoblastoid
interferon in the treatment ofsmall cell lung cancer. Br J Cancer 47:361-366, 1983
225. Mattson K, Holsti LR, Niiranen A, et al: Human leukocyte interferon as part ofa combined treatment
for previously untreated small cell lung cancer. J Biol Resp Modif4:8-17, 1985
226. Neefe JR, Silgals R, Ayoob M, Schein PS: Minimal activity of recombinant clone A interferon in
metastatic colon cancer. J Biol Resp Modif 3:366-370, 1984
227. Eggermont AM, Weimar W, Marquet RL, et al: Phase II trial of high-dose recombinant leukocyte
alpha-2 interferon for metastatic colorectal cancer without previous systemic treatment. Cancer Treat
Rep 69:185-187, 1985
228. Silgals RM, Ahlgren JD, Neefe JR, et al: A phase II trial ofhigh-dose intravenous interferon alpha-2
in advanced colorectal cancer. Cancer 54:2257-2261, 1984
229. Chaplinski T, Laszlo J, Moore J, Silverman P: Phase II trial oflymphoblastoid interferon in metastatic
colon carcinoma. Cancer Treat Rep 67:1009-1012, 1983
230. Figlin RA, Callaghan M, Sarna G: Phase II trial ofa (human leukocyte) interferon administered daily
in adenocarcinoma ofthe colon/rectum. Cancer Treat Rep 67:493-494, 1983
231. Lundell G, Blomgren H, Cedermark B, Silfversward C. Theve T, Ohman U: High dose rDNA human
alpha 2 interferon therapy in patients with advanced colorectal adenocarcinoma: A phase II study.
Radiother Oncol 1:325-332, 1984
232. Furue H: Phase II studies of interferon alpha-2 Sch 30500 in advanced gastrointestinal carcinoma.
Gan To Kagaku Ryoho 12:1625-1629, 1985
233. Gutterman J, Quesada J: Clinical investigation of partially pure and recombinant DNA derived
leukocyte interferon in human cancer. Texas Rep Biol Med 41:626-633, 1981-82
234. Chang AY, Fisher HA, Spiers AS, Boros L: Toxicity of human recombinant interferon alpha-2 in
patients with advanced prostate carcinoma. J Interferon Res 6:713-715, 1986
235. Lyons SF, Schoub BD, Kew MC, Sachs E, Chiu MN, Crespi M: The use of interferon functional
assays in the laboratory monitoring ofpatients with hepatocellular carcinoma receiving interferon. Am
J Clin Pathol 85:450-455, 1986